Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data-Reference-Cited by-同舟云学术

Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data

Published:2020-03-12 Issue:3 Volume:15 Page:e0229973
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Roberto Giuseppe,Spini Andrea,Bartolini Claudia,Moscatelli Valentino,Barchielli Alessandro,Paoletti Davide,Giorgi Silvano,Fabbri Alberto,Bocchia Monica,Donnini Sandra,Gini Rosa,Ziche Marina^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. MabThera–Summary of Product Characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000165/WC500025821.pdf

2. Clinical review: Serious adverse events associated with the use of rituximab—a critical care perspective;PM Kasi;Crit Care,2012

3. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma;JD Hainsworth;Clin Lymphoma Myeloma Leuk,2014

4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;M Pfreundschuh;Lancet Oncol,2006

5. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial;G Salles;Lancet,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project;Clinical Epidemiology;2024-06

2. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project;Pharmacological Research;2024-02

3. Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications;Frontiers in Oncology;2023-05-31

4. First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective;Cancers;2021-12-05

5. Pharmacoepidemiology for oncology clinical practice: Foundations, state of the art and perspectives;Therapies;2021-11